Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a biotechnology company with a strong focus on research and development. The company leverages its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs that target viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta is at the forefront of developing novel inhibitors aimed at combating the hepatitis C virus (HCV), among other conditions.
Enanta's portfolio includes several classes of direct-acting antiviral (DAA) inhibitors, such as protease inhibitors, NS5A inhibitors, and nucleotide polymerase inhibitors. These are complemented by a host-targeted antiviral (HTA) inhibitor class specifically designed against cyclophilin. One of the company's most notable achievements is the development of paritaprevir, a lead protease inhibitor that is a key component of AbbVie's approved HCV treatment regimen.
In addition to HCV, Enanta is actively pursuing treatments for other serious conditions. The company has a preclinical program targeting non-alcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage due to fat buildup. Enanta's research also extends to hepatitis B and the respiratory syncytial virus (RSV), broadening its impact on viral and liver diseases.
Enanta operates in partnership with AbbVie, which markets its protease inhibitors, while other promising drug candidates are progressing through the development pipeline. The company's commitment to innovation and strategic collaboration positions it as a significant player in the biotech industry.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company, has announced its participation in three upcoming investor conferences in September 2024. The company's management will be involved in fireside chats at the following events:
- Baird 2024 Global Healthcare Conference on September 10 at 2:35 p.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 10:00 a.m. ET
- 2024 Cantor Global Healthcare Conference on September 17 at 10:55 a.m. ET
Live webcasts of these events will be available on the 'Events and Presentations' section of Enanta's website. Replays will be archived for at least 30 days after the presentations.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for its fiscal third quarter ended June 30, 2024. Total revenue was $18.0 million, consisting of royalty revenue from AbbVie's HCV regimen MAVYRET/MAVIRET. The company reported a net loss of $22.7 million, or $1.07 per diluted share. Enanta's cash and marketable securities totaled $272.6 million as of June 30, 2024.
Key highlights include:
- Completion of enrollment for RSVPEDs, a Phase 2 study of zelicapavir in pediatric RSV patients
- Completion of EDP-323 Phase 2a Challenge Study in RSV
- Advancement of KIT inhibitors for chronic spontaneous urticaria
- Expected cash runway through Q3 2027
Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs for virology and immunology, has announced its participation at the Jefferies Global Healthcare Conference. The event will feature a fireside chat with President and CEO Jay R. Luly, Ph.D., and Chief Product Strategy Officer Tara L. Kieffer, Ph.D. The session is set for June 5, 2024, at 7:30 a.m. ET in New York, NY. A live webcast of the discussion will be available on Enanta's website, with a replay accessible for at least 30 days post-event.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in the JMP Securities Life Sciences Conference with their CEO and Chief Product Strategy Officer, discussing small molecule drugs for virology and immunology. The event will be live webcasted and available for replay on Enanta's website.
Enanta Pharmaceuticals, a clinical-stage biotechnology company, reported financial results for Q2 of fiscal year 2024. The company anticipates reporting topline data from RSV studies, phase 2 study of Zelicapavir, and CSU development candidate selection in 2024. Enanta's revenue was $17.1 million, with research and development expenses of $35.6 million. The company's operations are supported by $300.3 million in cash and marketable securities. Enanta is focused on advancing antiviral treatments for RSV and immunology indications.
Enanta Pharmaceuticals, Inc. announced inducement grants to its new Chief Legal Officer, Matthew P. Kowalsky, involving stock options, performance share units, and relative total stockholder return units under the company's 2024 Inducement Stock Incentive Plan. These awards are aimed at incentivizing Mr. Kowalsky's performance and retention within the company.
Enanta Pharmaceuticals, Inc. announced the appointment of Matthew P. Kowalsky as Chief Legal Officer. With over 20 years of legal experience in the life sciences industry, he will lead all legal and compliance activities for Enanta, providing strategic guidance and corporate governance oversight. Kowalsky's background includes roles at Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals, and Lantheus Medical Imaging, among others. His expertise in corporate governance, public company reporting, intellectual property, financing, and business development makes him a valuable addition to Enanta's leadership team.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) will host a conference call on May 6 at 4:30 p.m. ET to discuss its financial results for its fiscal second quarter ended March 31, 2024. Enanta is a clinical-stage biotechnology company focused on small molecule drugs for virology and immunology indications. The results will be reported after the U.S. market closes on May 6, 2024. The call will update on Enanta’s business, research, and development pipeline.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
What is the focus of Enanta Pharmaceuticals?
Where is Enanta Pharmaceuticals located?
What are some of the diseases Enanta targets?
What is paritaprevir?
Does Enanta collaborate with other companies?
What is Enanta’s approach to drug discovery?
What is NASH?
What are DAAs?
What is an HTA inhibitor?
What makes Enanta significant in the biotech industry?
